Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Prognostic models for diffuse large B-cell lymphoma.

A Conconi1, E Zucca, E Roggero

  • 1Istituto Oncologico della Svizzera Italiana, Divisione di Oncologia Medica, Ospedale San Giovanni, Bellinzona, Switzerland.

Hematological Oncology
|August 29, 2000
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Metabolic heterogeneity-based radiomic model predicts treatment outcomes of primary mediastinal B-cell lymphoma patients in the IELSG37 study.

British journal of haematology·2026
Same author

Left and right-side echocardiographic measurement of pulmonary artery stiffness in thoroughbred racehorses.

Journal of equine veterinary science·2026
Same author

A multicenter retrospective analysis of recurrent/metastatic nasopharyngeal cancer from non-endemic areas: Results in the pre-immunotherapy era.

European journal of cancer (Oxford, England : 1990)·2025
Same author

Spontaneous intraoperative ventricular haematoma in a neonate.

BMJ case reports·2025
Same author

Lymphomas: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.

Annals of oncology : official journal of the European Society for Medical Oncology·2025
Same author

Survival of European children, adolescents and young adults diagnosed with haematological malignancies in the period 2000-2013: Results from EUROCARE-6, a population-based study.

European journal of cancer (Oxford, England : 1990)·2025
Same journal

Integrated Glycoproteomics Identifies Dynamic IgA1 N-Glycosylation and FUT8 as a Functional Mediator in Multiple Myeloma.

Hematological oncology·2026
Same journal

Sustained Complete Response in Refractory Idiopathic Multicentric Castleman Disease Following a Single CD19 CAR T-Cell Infusion: A Case Report With Mechanistic Insight.

Hematological oncology·2026
Same journal

Efficacy and Safety of Novel-Agent-Based Front-Line Therapy in Older Adults Aged ≥ 60 Years With Classic Hodgkin Lymphoma: A Systematic Review and Meta-Analysis.

Hematological oncology·2026
Same journal

Extracorporeal Cytokine Hemadsorption for the Treatment of Severe Steroid Refractory Cytokine Release Syndrome Secondary to T-Cell Immunotherapy for B-Cell Malignancies: A Case Series.

Hematological oncology·2026
Same journal

Glofitamab Induces Complete Responses in Relapsed and Refractory Primary Central Nervous System Lymphoma.

Hematological oncology·2026
Same journal

Impact of U2AF1 Pathogenic Variants on Prognosis of Myelodysplastic Neoplasms With RUNX1 Mutation.

Hematological oncology·2026
See all related articles

The International Prognostic Index (IPI) can predict Diffuse Large B-cell Lymphoma (DLBCL) patient outcomes. Adding serum beta-2 microglobulin (beta-2M) to the IPI improves its ability to identify high-risk DLBCL patients.

Area of Science:

  • Oncology
  • Hematology
  • Clinical Research

Background:

  • Prognosis for Diffuse Large B-cell Lymphoma (DLBCL) patients varies significantly.
  • Several pretreatment variables have been integrated into prognostic models to predict patient mortality risk.
  • The International Prognostic Index (IPI) is a widely accepted prognostic model for DLBCL.

Purpose of the Study:

  • To compare the sensitivity and specificity of major prognostic models for DLBCL.
  • To evaluate the potential improvement of the IPI by incorporating serum beta-2 microglobulin (beta-2M) levels.
  • To identify a more accurate prognostic tool for DLBCL patients.

Main Methods:

  • A cohort of 111 DLBCL patients uniformly treated with a CHOP-like regimen was analyzed.
  • Major DLBCL prognostic models were applied to the patient cohort.

Related Experiment Videos

  • The International Prognostic Index (IPI) was evaluated with and without the addition of serum beta-2 microglobulin (beta-2M).

    • Main Results:

    • The beta-2M-IPI model demonstrated improved sensitivity (73%) compared to the standard IPI (45%) in predicting treatment failures.
    • This improvement in sensitivity was achieved without a significant loss in specificity.
    • The beta-2M-IPI model showed potential for identifying patients with very poor prognoses.

    Conclusions:

    • The beta-2M-IPI model may be a valuable tool for identifying DLBCL patients at higher risk of treatment failure.
    • Incorporating serum beta-2M levels into the IPI can enhance risk stratification for DLBCL.
    • This improved prognostic assessment may aid in selecting patients who require tailored therapeutic strategies.